Aperio Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Aperio Group’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-17,170	Closed	-$65K	–	2424
2020 Q1	$65K	Sell	17,170 -9,606	-36%	-$41.4K	﹤0.01%	2258
2019 Q4	$136K	Sell	26,776 -556	-2%	-$2.94K	﹤0.01%	2246
2019 Q3	$138K	Sell	27,332 -6,511	-19%	-$32.5K	﹤0.01%	2217
2019 Q2	$209K	Buy	33,843 +4,378	+15%	+$21.1K	﹤0.01%	2161
2019 Q1	$137K	Sell	29,465 -407	-1%	-$1.84K	﹤0.01%	2213
2018 Q4	$125K	Buy	+29,872	New	+$152K	﹤0.01%	2203
2018 Q1	–	Sell	-16,653	Closed	-$99K	–	2281
2017 Q4	$99K	Buy	16,653 +584	+4%	+$3.55K	﹤0.01%	2210
2017 Q3	$118K	Buy	+16,069	New	+$102K	﹤0.01%	2177

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Aperio Group's PGNX Position: Q2 2020 in Review

Aperio Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 17,170 shares — an estimated $65K sold.

Aperio Group first reported a position in PGNX in Q3 2017 and held it in 8 quarters. The position peaked at $209K in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Aperio Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Aperio Group sold 17,170 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $65K.
Aperio Group first reported a position in Progenics Pharmaceuticals Inc in Q3 2017 and held it in 8 quarters.
Aperio Group's Progenics Pharmaceuticals Inc position peaked at $209K in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Aperio Group's 13F filing for Q2 2020, filed 13 Aug 2020.